Aurobindo has reached a deal to purchase four investigational biosimilars from TL Biopharmaceutical for an undisclosed amount, as reported Business Standard Thursday.
Under the agreed terms, TL will supply all the developmental data for the four molecules, while Aurobindo will develop, commercialise and market the products globally.
The therapies are targeted for regulatory submissions between 2020 and 2022.
Aurobindo plans to initiate clinical studies of the lead compound in the transaction, a biosimilar of bevacizumab, later this year.
"We are impressed with the TL product development as these products are developed to the highest standards of biosimilarity," said Aurobindo managing director N Govindarajan, adding "this acquisition is in line with our strategy of investing in complex products and is an important first step towards establishing Aurobindo's global biosimilar portfolio."
To read more NewsPoints articles, click here.